Scienture
Yahoo Finance • 8 days ago
SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market
Arbli™ is the first and only ready-to-use liquid formulation of losartan, eliminating the need for compounding while offering reduced dosing volume and extended room-temperature shelf life COMMACK, NY, Sept. 16, 2025 (GLOBE NEWSWIRE) --... Full story
Yahoo Finance • 8 days ago
EXCLUSIVE: Scienture Secures PBM-Led Rebate Agreement To Position Hypertension Drug For Rapid Adoption In US Market
Scienture Holdings, Inc. (NASDAQ:SCNX) on Tuesday announced that it has formalized a commercial Pharmacy Benefit Manager (PBM) led Group Purchasing Organization (GPO) rebate agreement, advancing the process of securing formulary access wit... Full story
Yahoo Finance • 30 days ago
Scienture Holdings files to sell 2.1M shares for holders
* Scienture Holdings (NASDAQ:SCNX [https://seekingalpha.com/symbol/SCNX]) on Friday filed a registration statement [https://seekingalpha.com/filing/10337129] related to the resale of up to 2,097,317 company shares by certain selling stoc... Full story
Yahoo Finance • last month
Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock
Commack, NY, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Scienture Holdings, Inc. (Nasdaq: SCNX) (“Scienture” or the “Company”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to p... Full story
Yahoo Finance • last month
SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.
COMMACK, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregive... Full story
Yahoo Finance • 2 months ago
Scienture secures $1.2 million in bridge funding
* Scienture (NASDAQ:SCNX [https://seekingalpha.com/symbol/SCNX]) has approved a bridge funding raise of up to an aggregate amount of $3M, of which it has secured about $1.2M, through the issuance of shares of the company’s common stock t... Full story
Yahoo Finance • 2 months ago
Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding
Commack, NY, July 24, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physici... Full story
Yahoo Finance • 2 months ago
Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements
Commack, NY, July 16, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physici... Full story
Yahoo Finance • 3 months ago
Scienture Holdings terminates equity line of credit ahead of product launch
TAMPA - Scienture Holdings, Inc. (NASDAQ:SCNX), currently trading at $1.05 per share after falling over 90% in the past year, has terminated its Equity Line of Credit (ELOC) facility effective May 22, 2025, according to a company announcem... Full story
Yahoo Finance • 3 months ago
Scienture Holdings Announces Cancelation of ELOC
TAMPA, FL, June 17, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicia... Full story
Yahoo Finance • 4 months ago
SCIENTURE Announces Executive Leadership Transition
TAMPA, FL, May 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physician... Full story
Yahoo Finance • 6 months ago
SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC.
TAMPA, FL, April 08, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physici... Full story
Yahoo Finance • 6 months ago
Scienture Holdings, Inc. Issues Annual Letter to Shareholders
TAMPA, FL, April 03, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregiver... Full story
Yahoo Finance • 6 months ago
SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization
TAMPA, FL, March 25, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physici... Full story
Yahoo Finance • 6 months ago
Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days
TAMPA, FL, March 19, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregive... Full story
Yahoo Finance • 8 months ago
Scienture Holdings, Inc. Announces Dr. Narasimhan Mani’s Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics
TAMPA, FL, Jan. 21, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a Specialty Pharma company with a novel pipeline of brand products, is pleased to announce the participation of Narasimhan Mani, Ph.D., MBA (President... Full story
